Association between Bax degradation activity, established prognostic markers and clinical outcome
| Bax degradation activity . | Binet stage A vs (B and C) . | IgVH mut/unmut . | ZAP-70, −/+ . | CD38, −/+ . | LDT more than 12/less than 12 . | Karyotype other/11q-, 17p- . | Treatment no/yes . | Survival alive/dead . |
|---|---|---|---|---|---|---|---|---|
| Positive (n = 26) | 16/10 | 11/9 | 14/12 | 11/15 | 11/15 | 20/6 | 7/19 | 17/9 |
| Negative (n =14) | 13/1 | 5/4 | 10/3 | 11/3 | 10/4 | 14/0 | 7/7 | 13/1 |
| P value | .06* | .65* | .29 | .06 | .15 | .07* | .18* | .07* |
| Bax degradation activity . | Binet stage A vs (B and C) . | IgVH mut/unmut . | ZAP-70, −/+ . | CD38, −/+ . | LDT more than 12/less than 12 . | Karyotype other/11q-, 17p- . | Treatment no/yes . | Survival alive/dead . |
|---|---|---|---|---|---|---|---|---|
| Positive (n = 26) | 16/10 | 11/9 | 14/12 | 11/15 | 11/15 | 20/6 | 7/19 | 17/9 |
| Negative (n =14) | 13/1 | 5/4 | 10/3 | 11/3 | 10/4 | 14/0 | 7/7 | 13/1 |
| P value | .06* | .65* | .29 | .06 | .15 | .07* | .18* | .07* |
Data are numbers in each group. An LDT less than 12 includes cases where treatment was started before LDT could be assessed. The Binet clinical stage was that at diagnosis. IgVH used less than 2% as the threshold for unmutated versus mutated.
11q- indicates 11q22 deletion by FISH or G-banding; and 17p-, 17p13 deletion by FISH or G-banding.
Tests were 2-sided Fisher exact test; otherwise P values were obtained using chi-square with Yates correction.